logo

For the Inventor, By the Inventor

Red Bank, NJ, United States of America

Richard A Mumford

USPTO Granted Patents = 19 


Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 134(Granted Patents)


Company Filing History:

goldMedal19 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal1 out of 2,100 
 
University of Washington
 patents
where one patent can have more than one assignee

Years Active: 1992-2012

Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents
1. 8283344 - Method of treating inherited severe neutropenia (2012-10-09),
2. 7514409 - VLA-4 antagonists (2009-04-07),
3. 6943180 - Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors (2005-09-13),
4. 6903075 - Heterocyclic amide compounds as cell adhesion inhibitors (2005-06-07),
5. 6855708 - N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors (2005-02-15),
6. 6645939 - Substituted &bgr;-alanine derivatives as cell adhesion inhibitors (2003-11-11),
7. 6559174 - N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors (2003-05-06),
8. 6348570 - Chromophore containing compounds and their use in determining interleukin-1&bgr; convertase activity (2002-02-19),
9. 6291511 - Biarylalkanoic acids as cell adhesion inhibitors (2001-09-18),
10. 6221888 - Sulfonamides as cell adhesion inhibitors (2001-04-24),
11. 6124107 - Assay for marker of human polymorphonuclear leukocyte elastase activity (2000-09-26),
12. 5766909 - DNA encoding inducible nitric oxide synthase (1998-06-16),
13. 5420010 - Assay for evaluating inhibition of polymorphonuclear leukocyte elastase (1995-05-30),
14. 5387504 - Monospecific antibodies and assay system for detecting stromelysin (1995-02-07),
15. 5276139 - Haptens useful in evaluating inhibition of PNN elastase by N-substituted (1994-01-04),

Title: The Inventor Profile: Richard A Mumford

Introduction:

Richard A Mumford, a prolific inventor based in Red Bank, NJ, is renowned for his groundbreaking work in the field of medical treatments. With an impressive portfolio of 19 patents, Mumford has significantly contributed to the advancement of healthcare solutions.

Latest Patents:

Among his latest patents is a revolutionary method for treating inherited severe neutropenia. This groundbreaking invention focuses on treating severe neutropenia, including cyclic neutropenia and severe congenital neutropenia, by administering a specific compound or its salt. Additionally, Mumford's VLA-4 antagonists have shown promise in inhibiting cell adhesion and addressing various inflammatory conditions such as ulcerative colitis, Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.

Career Highlights:

Mumford's illustrious career has seen him collaborate with esteemed institutions and companies. He has made significant contributions during his tenure at Merck & Company, Inc., where his innovative spirit flourished. Additionally, his affiliation with the University of Washington underscores his commitment to advancing medical research and innovation.

Collaborations:

Throughout his career, Richard A Mumford has worked closely with notable colleagues such as William K Hagmann and Malcolm MacCoss. These collaborative efforts have led to the development of pioneering medical solutions that have the potential to impact global healthcare.

Conclusion:

In conclusion, Richard A Mumford's remarkable journey as an inventor showcases his dedication to pushing the boundaries of medical science. His impactful patents and collaborations epitomize his passion for innovation and his relentless pursuit of creating transformative solutions for complex medical challenges. Mumford's pioneering work continues to inspire future generations of inventors and researchers in the quest for improving human health and well-being.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…